Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab.

Jie LiMaoguang MaXuesong YangMaolei ZhangJingyan LuoHuangkai ZhouNunu HuangFeizhe XiaoBingquan LaiWeiming LvNu Zhang

Published in: Molecular cancer (2020)

Our results not only demonstrated that certain TNBCs were not truly 'HER2 negative' but also highlighted the clinical implications of Pertuzumab in circ-HER2/HER2-103 expressing TNBC patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
epidermal growth factor receptor
prognostic factors
metastatic breast cancer
patient reported